Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SI | P14410 | 2/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668483 | 0.88 | TSHR (0.36) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL3410284 | 0.86 | TSHR (0.46) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL6668476 | 0.83 | TDP1 (0.42) | SMN1; SMN2KMT2AMAPT | |
| SCHEMBL10995272 | 0.80 | SMN1; SMN2 (0.46) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL9212731 | 0.80 | SMN1; SMN2 (0.43) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL9788306 | 0.80 | TSHR (0.40) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL17000160 | 0.80 | SMN1; SMN2 (0.43) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL5513850 | 0.80 | SMN1; SMN2 (0.43) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL21427132 | 0.78 | TDP1 (0.42) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL19035870 | 0.78 | TDP1 (0.42) | TSHRMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100172851-A1 | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites | YU RUEY J | 2010-07-08 | — | — | US | claimed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024063100-A1 | METHOD FOR PRODUCING POLYVALENT CARBODIIMIDE B | 旭化成株式会社 | 2024-03-28 | — | — | WO | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-20230135772-A1 | CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4130154-A1 | CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT | Asahi Kasei Kabushiki Kaisha (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115190901-A | Carbodiimide composition, curing agent composition, coating composition, and resin cured product | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-20070093551-A1 | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites | YU RUEY J | 2007-04-26 | — | — | US | disclosed |
| WO-2007047486-A2 | HYDROXY-OLIGOCARBOXYLIC ESTERS: EFFECTS ON NERVE AND USE FOR CUTANEOUS AND MUCOCUTANEOUS ORGANS OR SITES | YU RUEY J (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
| EP-0831767-B1 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | YU RUEY J (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-0831767-A4 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | YU RUEY J (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0831767-A1 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | Yu, Ruey J., Dr. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5686489-A | TOPICALLY APPLIED TO INDUCE GLYCOSAMINOGLYCAN, PROTEOGLYCAN, COLLAGEN AND ELASTIN BIOSYNTHESIS; WRINKLE RESISTANCE | TRISTRATA TECHNOLOGY, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1996040047-A1 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | YU RUEY J (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | CD38, PARP9, MCCC2 | TSHR 4705/4885MGAM 1246/4885GAA 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.